Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Phase 4 Completed 180 enrolled Emory University Novo Nordisk A/S · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if treatment with degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes who are admitted to the hospital and then transition to home after discharge from the hospital.

Timeline

Start: 2018-01-02
Primary completion: 2021-03-01
Completion: 2021-03-01

Publications

Results Galindo RJ, Pasquel FJ, Vellanki P, Alicic R, Lam DW, Fayfman M, Migdal AL, Davis GM, Cardona S, Urrutia MA, Perez-Guzman C, Zamudio-Coronado KW, Peng L, Tuttle KR, Umpierrez GE. Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes. Diabetes Obes Metab. 2022 Jan;24(1):42-49. doi: 10.1111/dom.14544. Epub 2021 Sep 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Degludec	Protein / enzyme biologic	80 %	—
Subject	Degludec	Protein / enzyme biologic	100 %	—
Comparator	insulin glargine	Protein / enzyme biologic	80 %	—
Comparator	insulin glargine	Protein / enzyme biologic	100 %	—
Background	insulin aspart	Protein / enzyme biologic	—	—

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications